Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.
![Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News](https://retinafoundation.org/wp-content/uploads/2017/10/Mason-Two-Crow.jpg)
Related Articles
Promising Results From Ongoing Phase 1/2 Clinical Trial for X-Linked Retinitis Pigmentosa (XLRP) Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News Retina Foundation Announces 2023 Visionary Luncheon and Sets $1 Million Fundraising Goal Recently@Retina Newsletter November 2023 Retina Foundation 20/20 Video Research Updates